Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmketamine dose study for remifentanil-induced hyperalgesia in thoracoscopic surgery by time of day
ChiCTR2400083093Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Chongqing Medical University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in hyperalgesia (6 arms), sponsored by The Third Affiliated Hospital of Chongqing Medical University. Primary endpoint: Postoperative 24-hour area under the curve of movement pain NRS. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
hyperalgesia
Beyond the preview
Go deeper on ChiCTR2400083093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083093.